Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atrium TherapeuticsRNA -3.29%12 EV-to-OCF is 1.27 as of Jul. 21, 2026, which is 87% above its 10-year median of 0.68. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Atrium Therapeutics ranks worse than 77.82% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Atrium Therapeutics's Enterprise Value is $-64.01 Mil.
Atrium Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-50.40 Mil. Therefore, Atrium Therapeutics's EV-to-OCF for today is 1.27.
The historical rank and industry rank for Atrium Therapeutics's EV-to-OCF or its related term are showing as below:
RNA'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.3 Med: 0.68 Max: 1.27
Current: 1.27
During the past 3 years, the highest EV-to-OCF of Atrium Therapeutics was 1.27. The lowest was 0.30. And the median was 0.68.
RNA's EV-to-OCF is ranked worse than 77.82% of 1411
companies
in the Biotechnology industry
Industry Median: -3.33
vs RNA: 1.27
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Atrium Therapeutics's PE Ratio (TTM) for today is calculated as:
Atrium Therapeutics's share price for today is $11.76.
Atrium Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Atrium Therapeutics EV-to-OCF Related Terms
Atrium Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atrium Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's EV-to-OCF falls into.
Atrium Therapeutics's current Enterprise Value is $-64.01 Mil.
Atrium Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrium Therapeutics (RNA) has a EV-to-OCF of 1.27 as of Jul. 21, 2026. This is 87% above median its historical median of 0.68. Over the past decade, Atrium Therapeutics' EV-to-OCF has ranged from 0.30 to 1.27. According to the industry distribution chart, Atrium Therapeutics ranks #1098 out of 1411 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Atrium Therapeutics' EV-to-OCF too high?
Atrium Therapeutics' current EV-to-OCF of 1.27 is 87% above median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 1.27. Based on the distribution chart, Atrium Therapeutics ranks #1098 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' EV-to-OCF compare to CNTN and QTTB?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #1098 out of 1411 companies for EV-to-OCF. This places Atrium Therapeutics in the lower half of its industry. Historically, Atrium Therapeutics' own EV-to-OCF has ranged from 0.30 to 1.27 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Atrium Therapeutics's current EV-to-OCF is 1.27, which is 87% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current EV-to-OCF of 1.27. The current EV-to-OCF is 1.27, which is 87% above median its 10-year median of 0.68. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current EV-to-OCF is 1.27 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 
